Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months

Vaccine

Volumn 28, Issue 36, 2010, Pages 5837-5844

  Carmona, Alfonso ^a   Omeñaca, Félix ^b   Tejedor, Juan C ^c   Merino, Jose M ^d   Vaman, Tejaswini ^e   Dieussaert, Ilse ^e   Gillard, Paul ^e   Arístegui, Javier ^f  

^a Instituto Hispalense de Pediatria   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL DE MÓSTOLES   (Spain)

^d HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f HOSPITAL DE BASURTO   (Spain)

Author keywords

Adjuvant; Children; Influenza vaccines

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; TOCOPHEROL;

ARTICLE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG FEVER; DRUG SAFETY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INJECTION SITE PAIN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SWELLING; TRAUMATIC BRAIN INJURY; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; POLYSORBATES; SQUALENE;

EID: 77955560311     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.065     Document Type: Article

References (49)

1. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine. Lancet 2007, 370:580-589.
2. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 2009, 4:e4384. 10.1371/journal.pone.0004384.
3. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008, 198:642-649.
4. Germann T.C., Kadau K., Longini I.M., Macken C.A. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 2006, 103:5935-5940.
5. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., Burke D.S. Strategies for mitigating an influenza pandemic. Nature 2006, 442:448-452.
6. Osterhaus A. Pre- or post-pandemic influenza vaccine? Editorial. Vaccine 2007, 25:4983-4984.
7. Jennings L.C., Monto A.S., Chan P.K.S., Szucs T.D., Nicholson K.G. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008, 8:650-658.
8. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
9. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
10. A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010, 28:1740-1745.
11. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(25):2605-2615. Novel Swine-Origin Influenza A (H1N1) Virus Investigation, Erratum in: N Engl J Med 2009;361(1):102.
12. Fraser C., Donnelly C.A., Cauchemez S., Hanage W.P., Van Kerkhove M.D., Hollingsworth T.D., et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009, 324:1557-1561.
13. Domínguez-Cherit G., Lapinsky S.E., Macias A.E., Pinto R., Espinosa-Perez L, de la Torre A., et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009, 302:1880-1887.
14. Kumar A., Zarychanski R., Pinto R., Cook D.J., Marshall J., Lacroix J., et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009, 302:1872-1879.
15. Echevarría-Zuno S., Mejía-Aranguré J.M., Mar-Obeso A.J., Grajales-Muñiz C., Robles-Pérez E., González-León M., et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009, 374:2072-2079.
16. Donaldson L.J., Rutter P.D., Ellis B.M., Greaves F.E., Mytton O.T., Pebody R.G., et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009, 339:b5213.
17. Bhat N., Wright J.G., Broder K.R., Murray E.L., Greenberg M.E., Glover M.J., et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005, 353:2559-2567.
18. Rojo J.C., Ruiz-Contreras J., Fernǎ́ndez M.B., Marin M.A., Folgueira L. Influenza-related hospitalizations in children younger than three years of age. Pediatr Infect Dis J 2006, 25:596-601.
19. Coffin S.E., Zaoutis T.E., Rosenquist A.B., Heydon K., Herrera G., Bridges C.B., et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics 2007, 119:740-748.
20. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009, 58(RR-10):1-8.
21. Nicoll A. Children, avian influenza H5N1 and preparing for the next pandemic. Arch Dis Child 2008, 93:433-438.
22. American Academy of Pediatrics. Pandemic influenza: warning, children at-risk; October 2007 (accessed May 10th, 2010 at ). http://www.aap.org/new/KidsPandemicFlufnl.pdf.
23. Basta N.E., Chao D.L., Halloran M.E., Matrajt L., Longini I.M. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol 2009, 170:679-686.
24. Loeb M., Russell M.L., Moss L., Fonseca K., Fox J., Earn D.J.D., et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010, 303:943-950.
25. Prevention control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009, 58(RR-08):1-52.
26. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
27. NIH Bulletin. Updated results: in youngest children, a second dose of 2009 H1N1 influenza vaccine elicits robust immune response (accessed May 10th, 2010 at ). http://www3.niaid.nih.gov/news/newsreleases/2009/interimpedsdata.htm.
28. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoché M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
29. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children. JAMA 2010, 303:37-46.
30. Schwarz T.F., Horacek T., Knuf M., Damman H.G., Roman F., Dramé M., et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009, 27(45):6284-6290.
31. Rümke H.C., Bayas J.M., de Juanes J.R., Caso C., Richardus J.H., Campins M., et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008, 26:2378-2388.
32. A-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults. Vaccine 2009, 27(52):7428-7435.
33. World Health Organization. Availability of a candidate reassortant vaccine virus for the novel Influenza A (H1N1) vaccine development X-179A (accessed November 19th, 2009, at ). http://www.who.int/csr/resources/publications/swineflu/candidates_X-179a/en/.
34. European Committee for Proprietary Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24; 2007.
35. Hehme N.W., Künzel W., Petschke F., Turk G., Raderecht C., Van Hoecke C., et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002, 22:751-769.
36. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(4):937-943.
37. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361. 1945-1952 and supplement.
38. FDA Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration May 2007 (accessed May 10th, 2010, at ). http://www.fda.gov/cber/gdlns/panfluvac.htm.
39. Study No 100351-056. A phase III double-blind, randomized, multicentric, comparative vaccination study of the immunogenicity and reactogenicity of a thiomersal free formulation of Influsplit SSW® 2003/2004 versus the standard formulation of Influsplit SSW® 2003/2004 in children aged from 6 months to <6 years (accessed May 10th, 2010, at ). http://www.gsk-clinicalstudyregister.com/files/pdf/3229.pdf.
40. Study No 104858 (Fluarix-US-005). A phase III, single-blind, randomized study to evaluate the immunogenicity and safety of Fluarix® (GSK Biologicals) compared with Fluzone® (Aventis Pasteur/Sanofi) administered intramuscularly in children (6 months and older) (accessed May 10th, 2010, at ). http://www.gsk-clinicalstudyregister.com/files/pdf/20022.pdf.
41. Gonzalez M., Pirez M.C., Ward E., Dibarboure H., García A., Picolet H. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child 2000, 83:488-491.
42. Mitchell D.K., Ruben F.L., Gravenstein S. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2002. Pediatr Infect Dis J 2005, 24:925-927.
43. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28:563-571.
44. ® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009, 27:6589-6594.
45. Zarocostas J. H1N1 pandemic flu found to cause viral pneumonia in severe cases, says WHO. BMJ 2009, 339:b4313.
46. Extracorporeal membrane oxygenation for 2009 Influenza A(H1N1) acute respiratory distress syndrome. JAMA 2009, 302(17):1888-1895. The Australia New Zealand Extracorporeal Membrane Oxygenation (ANZ. ECMO) Influenza Investigators.
47. Schwarz T.F., Horacek T., Knuf M., Damman H., Gillard P., Jilg W. Single-Dose primary vaccination with AS03A-adjuvanted prepandemic H5N1 influenza vaccine is sufficient to induce strong, rapid and broad immune response to booster vaccination after 12 Months. Influenza Vaccines for the World (IVW) 2009.
48. Díez-Domingo J., Garcés-Sanchez M., Baldó J.M., Planelles M.V., Ubeda I., JuBert A., et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (clade 1) AS03-adjuvanted pre-pandemic candidate influenza vaccines in children aged 3 to 9 years: a Phase II, randomized, open, controlled study. Pediatr Infect Dis J 2010, 29(6):e35-e46. 10.1097/INF.0b013e3181daf921.
49. Englund J.A., Walter E.B., Fairchok M.P., Monto A.S., Neuzil K.M. A Comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 2005, 115:1039-1047.